Rimegepant | B3303

Rimegepant is an oral antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM). It inhibits cAMP production stimulated by α-CGRP in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Romegepant has been approved by the U.S. FDA for the acute treatment of migraine.

Rimegepant is an oral antagonist of the calcitonin gene-related peptide (CGRP) receptor (Ki = 0.027 nM). It inhibits cAMP production stimulated by α-CGRP in SK-N-MC human neuroblastoma cells (IC50 = 0.14 nM). Romegepant has been approved by the U.S. FDA for the acute treatment of migraine.

B3303 | Rimegepant DataSheet

Alternate Name/Synonyms: (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-5H,6H,7H,8H,9H-cyclohepta[b]pyridin-9-yl 4-{2-oxo-1H,2H,3H-imidazo[4,5-b]pyridin-1-yl}piperidine-1-carboxylate BMS 927711

Appearance: Crystalline solid

Formulation:

CAS Number: 1289023-67-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₈H₂₈F₂N₆O₃

Molecular Weight: 534.6

Cell-Permeable?: TRUE

Purity: ≥98%

Solubilities: ~20 mg/ml DMSO

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: A calcitonin gene-related peptide (CGRP) receptor antagonist

MDL Number:

PubChem CID: 51049968

SMILES: C1CC(C2=C(C=CC=N2)C(C1C3=C(C(=CC=C3)F)F)N)OC(=O)N4CCC(CC4)N5C6=C(NC5=O)N=CC=C6

InChi: InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1

InChi Key: KRNAOFGYEFKHPB-ANJVHQHFSA-N